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Oncolytic viruses (OVs) are an emerging class of targeted anticancer therapies designed 
to selectively infect, replicate in, and lyse malignant cells without causing harm to normal, 
healthy tissues. In addition to direct oncolytic activity, OVs have shown dual promise as 
immunotherapeutic agents. The presence of viral infection and subsequently generated 
immunogenic tumor cell death trigger innate and adaptive immune responses that 
mediate further tumor destruction. However, antiviral immune responses can intrinsically 
limit OV infection, spread, and overall therapeutic efficacy. Host immune system can act 
both as a barrier as well as a facilitator and sometimes both at the same time based 
on the phase of viral infection. Thus, manipulating the host immune system to minimize 
antiviral responses and viral clearance while still promoting immune-mediated tumor 
destruction remains a key challenge facing oncolytic virotherapy. Recent clinical trials 
have established the safety, tolerability, and efficacy of virotherapies in the treatment of 
a variety of malignancies. Most notably, talimogene laherparepvec (T-VEC), a genetically 
engineered oncolytic herpesvirus-expressing granulocyte macrophage colony stimulat-
ing factor, was recently approved for the treatment of melanoma, representing the first 
OV to be approved by the FDA as an anticancer therapy in the US. This review discusses 
OVs and their antitumor properties, their complex interactions with the immune system, 
synergy between virotherapy and existing cancer treatments, and emerging strategies to 
augment the efficacy of OVs as anticancer therapies.
Keywords: oncolytic virus, cancer, immunotherapy, innate immunity, adaptive immunity
inTRODUCTiOn
Oncolytic viruses (OVs) are viruses that selectively infect and kill malignant cells, leaving sur-
rounding healthy cells unharmed. In addition to direct cytotoxic activity, OVs engage and amplify 
host immune responses, leading to the destruction of residual malignant cells and establishment 
of lasting antitumor immunity. Initial interest in the use of viruses to treat cancer dates back to 
observations made in the early 1900s of tumor regression in the context of natural viral infection (1). 
However, the feasibility of this approach was initially limited by viral pathogenicity and associated 
toxicity in human patients. Recent advances in genetic engineering technology enabling modifica-
tions that enhance the safety and efficacy of OVs spurred a renewed interest in oncolytic virotherapy 
(OVT). Improved tumor selectivity and inherent self-replication kinetics allow for targeted therapy 
and localized therapeutic amplification, reducing the risk of systemic toxicity.
Oncolytic viruses based on several different vectors including adenovirus, herpes simplex virus 
(HSV), vaccinia virus, Newcastle disease virus, measles virus, and reovirus have been shown to be 
tumor-specific, relatively non-toxic, and capable of inducing robust antitumor immune responses 
in animal models and human patients (2, 3). Talimogene laherparepvec (T-VEC), a genetically 
Table 1 | list of oncolytic viruses currently being tested in clinical trial.
virus name Phase Tumor Combination Reference
Adenovirus ONYX-015 III Squamous cell carcinoma  
head and neck (SCCHN)
Cisplatin Khuri et al. (4)
I/II Pancreatic cancer Gemcitabine Hecht et al. (5)
Pilot Advancer cancers Irinotecan + 5-FU or IL-2 Nemunaitis et al. (6)
I/II Advanced sarcoma Mitomycin-C, doxorubicin, cisplatin Galanis et al. (7)
Oncorine (H101) III SCCHN or esophageal cancer 5-fluorouracil + cisplatin or adriamycin Xia et al. (8)
Ad5-CD/Tkrep I Prostate cancer 5-fluorocytosine, valganciclovir, radiation Freytag et al. (9)
ONCOS-201 I Solid tumors Cyclophosphamide Ranki et al. (10)
Herpes simplex virus Talimogene laherparepvec I/II SCCHN Radiation, cisplatin Harrington et al. (11)
Ib Melanoma Ipilimumab (CTLA-4 inhibitor) Puzanov et al. (12)
G207 I Glioma Radiation Markert et al. (13)
Reovirus RT3D I/II Advanced cancers Carboplatin/paclitaxel Karapangiotou et al. (14)
Vaccinia GL-ONC1 I Head and neck carcinoma Cisplatin, radiotherapy NCT01584284
JX-594 (Pexa-Vec) I/IIa Colorectal cancer Irinotecan NCT01394939
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engineered HSV-based OV, was recently approved for the treat-
ment of melanoma, representing the first oncolytic virus to be 
approved by the FDA as an anticancer therapy. Numerous clinical 
trials (Table  1) have demonstrated synergy between OVT and 
other standard and emerging anticancer therapies (4–14). 
Combination treatment, particularly with immune-modulating 
therapies, continues to be a promising field of research.
Activation of the host immune system is a crucial component 
of OV-mediated tumor destruction. However, immune responses 
can also prematurely terminate OV infection, precluding thera-
peutic efficacy. Optimization of viral replication and propagation 
as well as the generation of anticancer immunity remains a sig-
nificant challenge facing OVT. With a better understanding of the 
complex immunological interactions between OVs, tumor cells, 
and the host immune system, the next generation of OVs will be 
poised to realize the full immunotherapeutic potential of OVT.
OnCOlYTiC viRUSeS
At the core of OVT is the natural propensity of viruses to infect 
malignant cells. This preference stems from an overlap between 
the cellular changes incurred during oncogenesis and those 
induced by viral infection. Cancer cells evolve to resist apoptosis 
and growth suppression, evade immune-mediated destruction, 
and proliferate indefinitely, characteristics also conducive to viral 
replication (15). Additionally, many tumors develop defects in 
cellular antiviral response pathways, like type I interferon (IFN) 
signaling, rendering them more susceptible to viral infection (16).
While some viruses, such as H1 autonomously replicating 
parvoviruses, reoviruses, Newcastle disease viruses (NDVs), 
vesicular stomatitis virus (VSV), mumps virus, etc., have a nat-
ural preference for infecting specific types of human tumor 
cells, others can be genetically modified to enhance tumor cell 
selectivity, including adenovirus, measles, vaccinia, and HSVs 
(3, 17). Various approaches have been explored for engineering 
the ideal oncolytic viral vector that will selectively target, infect, 
and destroy tumor cells, while sparing normal cells. Viral coat 
proteins can be altered to recognize specific tumor cell surface 
markers or utilize tumor-expressed proteases for cellular entry 
(3, 18). Genes necessary for viral replication can be placed under 
the control of tumor-specific promoters, or deleted entirely, 
rendering viral replication conditional upon genes constitutively 
active in malignant, but not normal, cells (3, 4).
Ovs anD TUMOR MiCROenviROnMenT 
(TMe)
virus-Mediated Tumor Cell Destruction
Oncolytic viruses mediate tumor cell death via direct and indi-
rect mechanisms, functioning as both direct cytotoxic agents 
and therapeutic cancer vaccines (Figure 1). These mechanisms 
are connected by the propensity of many OVs to induce immu-
nogenic forms of tumor cell death, including immunogenic 
apoptosis, necrosis, pyroptosis, and autophagic cell death, which 
activate host immune responses (19, 20). Immunogenic cell death 
(ICD) is characterized by cell surface exposure of calreticulin 
and heat shock proteins and the release of immune-stimulating 
molecules like ATP, uric acid, and high-mobility group box 1. 
Unlike normal apoptosis, which is mostly non-immunogenic and 
at time tolerogenic, ICD can induce antitumor immune response 
via dendritic cell (DC) activation. ICD of tumor cells also releases 
tumor-associated antigens (TAAs) that can be used to generate 
antigen-specific antitumor immunity (21–24).
native antigen-Presenting Cells (aPCs) 
and viruses
Antigen presenting cells, such as DCs, are crucial mediators 
of innate and adaptive immunity, facilitating the generation of 
immune responses by releasing cytokines and activating naïve 
T cells. Recruited to sites of infection and inflammation, such as 
those induced by immunogenic tumor cell death, DCs capture 
viral and tumor antigens released during oncolysis and present 
them to naïve T cells, thereby initiating the generation of antigen-
specific adaptive immune responses that mediate targeted 
destruction of residual and recurrent tumor cells (25).
FigURe 1 | Oncolytic viruses (Ovs) mediate tumor cell destruction by two main mechanisms: (1) direct lysis of infected cells, Ovs selectively infect 
malignant cells, hijacking their cellular transcription, and translation mechanisms in order to replicate. Termination of the viral replication cycle induces 
tumor cell lysis and release of infectious viral progeny. Oncolysis also releases viral particles, tumor-associated antigens, and cellular damage-associated molecular 
patterns like calreticulin, heat shock proteins, and cellular ATP in a highly inflammatory process, termed “immunogenic cell death” and (2) induction of host 
antitumor immune responses. Cellular detection of viral infection and the products of oncolysis trigger the rapid activation of host antiviral responses and influx of 
immune cells that mediate the destruction of residual infected and uninfected tumor cells. The direct recognition and killing of tumor cells is primarily mediated by 
natural killer cells of the innate immune system and tumor antigen-specific CD8+ cytotoxic T lymphocytes of the adaptive immune system.
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Tumor/virus-induced Cytokine Production
The TME is often characterized by a state of profound immu-
nosuppression. Tumors overexpress cytokines like interleukin-10 
and transforming growth factor-β (TGF-β), which inhibit natural 
antitumor immune responses. Tumor-derived cytokines and 
chemokines also include those promoting growth and vascu-
larization like tumor necrosis factor-α (TNF-α) and vascular 
endothelial growth factor (25).
Viral infection stimulates the release of cytokines (IL-1, IL-6, 
IL-12, IL-18, IFN-γ, and TNF-α) and chemokines (RANTES, 
MIP-1α/β) from infected cells and resident and infiltrating 
immune cells, altering the balance of pro- and anti-inflammatory 
factors within the TME (26, 27). In addition to direct antiviral 
and immunoregulatory activities, these compounds mediate the 
recruitment of cytokine-releasing immune cells with additional 
effector functions. Viral infection and resulting localized inflam-
mation enhance the effector functions of infiltrating immune 
cells, counteract tumor-induced immunosuppression, and facili-
tate the generation of antitumor immunity (27).
iMMUnOlOgiC baRRieRS TO 
SUCCeSSFUl OvT
Viral infection and oncolysis naturally activate innate and 
adaptive immune responses that are known to contribute to 
the killing of malignant cells. However, host immune responses 
to viral infection have also been shown to be detrimental to 
the overall efficacy of OVT. Numerous preclinical studies have 
demonstrated reduced viral replication, earlier clearance, and 
decreased antitumor efficacy in immunocompetent, compared to 
immunocompromised, hosts (2, 6, 28). Mechanisms of immuno-
logic barriers to successful OVT are shown in Figure 2. The avidity 
and timing of oncolysis and activation of different components of 
the host immune response seem to play vital roles in determining 
the nature and extent of their relative contributions to the overall 
efficacy of OVT, with vector species and malignancy-specific 
differences (29–31).
Ovs anD innaTe iMMUniTY
Detection of viral infection triggers the production of antiviral 
proteins, elaboration of cytokines, and recruitment of immune 
cells to the site of infection. Type I IFNs are antiviral proteins that 
reprogram gene expression in infected and uninfected cells to 
directly inhibit viral replication. IFNs also induce cell cycle arrest 
and apoptosis, upregulate major histocompatibility complex 
(MHC) expression, stimulate B cell immunoglobulin synthesis, 
and prompt the development and proliferation of memory T cells 
(27). Among first responders to viral infection are APCs and other 
innate immune cells, including neutrophils and NK cells (27, 32). 
In addition to the release of antiviral cytokines, these cells have 
unique mechanisms through which they can contribute to the 
antitumor efficacy of OVT. Neutrophils react to pathogens by 
secreting reactive oxygen species and proteases, inducing necrotic 
cell death and localized inflammation (4). In a heterotopic murine 
model of colon cancer, intratumoral neutrophil accumulation in 
response to OV infection resulted in tumor vasculature destruc-
tion and widespread tumor cell apoptosis (33). NK cells have also 
been shown to be key effectors of OV-induced antitumor immune 
responses (20, 23, 29). They specifically target cells lacking MHC 
molecules or displaying virally induced markers of cellular stress 
FigURe 2 | immunologic barriers to successful oncolytic virotherapy: (1) oncolytic virus delivery to tumor sites is impeded by the presence of neutralizing 
antibodies, complement proteins, and sequestration in organs such as the liver and spleen; (2) cellular antiviral responses, such as type I interferon 
signaling limits viral replication within tumor cells; (3) destruction of infected tumor cells by cells of the innate immune system (neutrophils, macrophages, 
NK cells) prematurely terminates viral infection; (4) tumor-induced immunosuppression (elaboration of immunosuppressive cytokines, accumulation of regulatory 
T cells, overexpression of negative checkpoint regulators of T cell function) inhibits the generation and effector functions of antigen-specific antitumor 
immune responses.
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like MIC-A/B, inducing cell death by releasing granzyme and 
perforin enzymes, and activating apoptosis-inducing receptors 
(27, 28, 34). The agonist/antagonist relationship of the immune 
system and OV is not static but evolves with the phase of the 
infection and tumor destruction.
Decreasing virus Clearance
In order to exert maximal therapeutic effects, OVs must persist 
long enough and induce sufficient oncolysis to stimulate the gen-
eration of long-lasting adaptive antitumor immunity. However, 
viruses are foreign pathogens and naturally elicit host immune 
responses mediating their clearance. Upon introduction to the 
body, viral particles become coated with neutralizing antibod-
ies and are eliminated in a complement-dependent fashion 
(35). Destruction of infected tumor cells by infiltrating innate 
immune cells and viral antigen-specific T cells can also terminate 
OV infection before full therapeutic effects have been achieved 
(33). Transient suppression of these early immune responses has 
potential to improve OV delivery to tumor sites, prolong viral 
infection, and enhance the overall therapeutic efficacy of OVT.
Inhibiting early intratumoral immune cell infiltration with 
low dose chemotherapy or TGF-β treatment has been shown to 
enhance viral replication, decrease clearance, and improve anti-
tumor outcomes in several murine models of glioma (32, 34, 36). 
A recombinant VSV vector expressing a broad-spectrum 
chemokine-binding protein had similar effects, substantially 
prolonging the survival of animals with multifocal hepatocellular 
carcinoma (37).
Pretreatment with immunosuppressive chemotherapeutics 
like cyclophosphamide has been shown to improve viral deliv-
ery, promote replication, and enhance oncolytic activity of HSV-
based OVs in murine models of glioma by depleting antiviral 
antibodies and impairing complement function (32, 38, 39) 
Viral coat modification through conjugation of polymers like 
polyethylene glycol and N-[2-hydroxypropyl]meth-acrylamide 
(HPMA) or lipid encapsulation can shield OVs from neutral-
izing serum factors and prevent the generation of new antiviral 
antibodies (2, 24). Alternatively, OVs can be hidden within 
carrier cell vectors and trafficked to tumor sites. In the context 
of malignant brain tumors, two cell types that have shown prom-
ising preclinical potential as OV carriers are mesenchymal stem 
cells (MSCs) (40) and neural stem cells (NSCs) (41). Both MSCs 
and NSCs possess a natural tropism for primary tumors and 
their metastases and are considered immune-privileged. MSCs 
have been studied extensively in preclinical settings (40, 42). In 
a small clinical trial of children with metastatic neuroblastomas 
refractory to frontline therapies, treatment with autologous 
MSCs carrying ICOVIR-5, an oncolytic adenovirus, was found 
to be safe and without significant systemic toxicity (43). For 
malignant glioma, NSC-based carriers not only improve the 
clinical efficacy of OV by protecting viruses from the host 
immune system but also through amplification of therapeutic 
payloads selectively at tumor sites (44, 45). In a comparison of 
MSCs and NSCs as cellular carriers for OVs, NSCs conferred a 
superior therapeutic efficacy in the context of malignant glioma 
(46). Based on these promising preclinical findings, the FDA 
recently approved the NSC HB1.F3-CD as a cell carrier carry-
ing CRAd-S-pk7 OV for clinical trials in patients with newly 
diagnosed malignant glioma.
Ov Plus Chemotherapy
Preclinical and clinical studies have demonstrated significantly 
enhanced antitumor immune and clinical responses in patients 
receiving combination chemotherapy and OVT (4, 7–11, 14). The 
first such human clinical trial evaluated ONYX-015 (d11520), a 
genetically modified adenovirus, in combination with cisplatin 
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and 5-fluorouracil in 37 patients with recurrent squamous cell 
head and neck cancer. Objective clinical responses were observed 
in 65% of treated patients, exceeding response rates seen with 
either agent alone (4). Chemotherapy complements virotherapy 
through a variety of known and unknown mechanisms, including 
the direct killing of malignant cells, enhancement of tumor cell 
immunogenicity, and suppression of antiviral immune responses 
(15, 47). Several chemotherapeutic agents, including oxaliplatin, 
doxorubicin, bleomycin, Bortezomib, and cyclophosphamide, 
have been shown to induce tumor ICD, promoting the generation 
of antitumor immune responses (19, 26, 48).
Ov Plus immune Checkpoint inhibitors
Destruction of malignant cells by the host immune system 
represents a crucial component of virotherapy. However, many 
tumors develop mechanisms to suppress the antitumor activity of 
incoming effector cells, for example by inducing overexpression 
of immune checkpoint regulators like CTLA-4 and PD-L1. T cell 
surface CTLA-4 competes with CD28 molecules for interaction 
with APC costimulatory molecules, transmitting inhibitory 
signals that suppress initial T cell activation. PD-L1, often over-
expressed by tumor cells and tumor-infiltrating lymphocytes, 
binds PD-1 on activated T  cells, inducing anergy or apoptosis 
(49, 50). Blockade of these molecules has been shown to improve 
T cell function and restore antitumor cellular immune responses. 
However, the clinical use of immune checkpoint inhibitors, 
particularly anti-CTLA-4 treatments, is limited by the high risk 
of associated severe autoimmune events resulting from systemic, 
uncontrolled T cell activation (50, 51). The unique ability of OVs 
to locally deliver and amplify therapeutic agents prompted an 
exploration of their use in combination with immune checkpoint 
inhibition. In a syngeneic murine model of malignant melanoma, 
the targeted, localized delivery of anti-CTLA-4 and anti-PD-L1 
antibodies to the TME via an oncolytic measles virus induced 
comparably robust antigen-specific antitumor immune responses 
without evidence of immune-mediated toxicity (50). In another 
murine model of melanoma, intratumoral injection of combina-
tion NDV OV and anti-CTLA-4 antibody treatment resulted 
in regression of primary injected tumors and contralateral, 
untreated tumors, prolonged survival, and enhanced protection 
from tumor rechallenge as compared to treatment with either 
agent alone (49).
Ov Plus Histone Deacetylase (HDaC) 
inhibitors
Histone deacetylase inhibitors are an emerging class of anti-
neoplastic agents that enhance the therapeutic efficacy of OVT 
primarily by suppressing the induction of IFN-stimulated genes 
(16). HDAC inhibitors have been shown to augment viral repli-
cation, reduce early intratumoral immune cell recruitment, and 
enhance the oncolytic activity of OVs in a variety of tumor types 
(16). As epigenetic modifiers of transcription, HDAC inhibitors 
also shift cellular profiles of gene expression to favor the induction 
of growth arrest and apoptosis in cancer cells, antagonize tumor 
angiogenesis, and enhance tumor cell immunogenicity through 
increased expression of MIC-A/B, MHC, and costimulatory 
molecules (52).
increasing antitumor immune Response
Following initial OV-mediated tumor debulking, it is advantageous 
to promote host immune system-mediated destruction of any 
residual or recurrent malignant cells. This can be accomplished by 
mitigating tumor-induced immunosuppression, enhancing tumor 
cell immunogenicity, or directly activating host immune responses. 
Interventions that promote the development of localized inflam-
mation can both counteract the immunosuppressive nature of the 
TME and recruit and activate effector immune cells. In a murine 
model of melanoma, OV expression of IL-12 and IL-18 increased 
intratumoral infiltration of activated NK cells, CD4+, and CD8+ 
T-cells, resulting in widespread tumor necrosis and prolonged 
survival (53). Combination treatment with other compounds that 
induce cellular stress or DNA damage, like chemotherapeutics, 
can enhance tumor immunogenicity by stimulating expression 
of NK  cell-activating ligands and provoking tumor ICD (48). 
Increasing the availability of TAAs within the TME via induction of 
ICD or OV expression of specific TAAs can enhance antigen pres-
entation and the generation of adaptive immunity. Incorporation 
of the ovalbumin protein within a VSV OV augmented the activa-
tion of ovalbumin-specific T cells, leading to increased antitumor 
effects in mice bearing B16ova tumors (54). Antigen-specific anti-
tumor immune responses can be further enhanced by successive 
vaccination with two different TAA-expressing viruses, in which 
the second OV heightens the antitumor effects generated by the 
primary vaccination. This “prime-boost” method has been shown 
to induce durable adaptive immune responses that primarily target 
TAAs, rather than viral antigens (31, 55).
Ovs anD aDaPTive iMMUniTY
Presentation of viral or TAA to cells of the adaptive immune 
system activates antigen-specific cellular and humoral immune 
responses. The primary antitumor effector cells of the adaptive 
immune system are CD8+ CTLs, which have been shown to be 
crucial mediators of OV-induced antitumor immunity, recognize 
specific antigens expressed on MHC class I molecules on the 
surface of infected and malignant cells and induce cell death 
through the release of perforin and granzymes. In the context 
of OVT, CTLs specific to viral antigens appear first, followed 
by development of TAA-specific CTLs (31). APCs also activate 
CD4+ T-helper cells, which release pro-inflammatory cytokines, 
promote CTL development, and are crucial in the development 
of antitumor immunity. Exposure to viral particles initiates 
humoral immune responses and the production of immuno-
globulins from activated B cells. These neutralizing or opsonizing 
antibodies inhibit viral function and facilitate the clearance of 
viral infection (2, 28).
neXT-geneRaTiOn iMMUne 
MODUlaTing OvT
The host immune response to viral infection remains both an 
untapped resource and significant challenge facing OVT. The 
antitumor effects of OVs can theoretically be maximized by miti-
gating early immune responses to allow OV replication, oncolysis, 
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and spread, followed by stimulation of the host immune system 
to destroy any residual tumor cells. Therapeutic manipulation 
of host immune responses represents a powerful strategy for 
optimizing both the oncolytic and immunotherapeutic potential 
of OVs. This can be achieved through combination therapy with 
chemotherapy, radiotherapy, immune checkpoint blockades, 
HDAC inhibitors, etc., or with single-agent OVs genetically 
engineered to express immune-modulating compounds.
In a murine model of colorectal cancer, OV expression of the 
chemokine RANTES (CCL5) prolonged the persistence of an onco-
lytic vaccinia virus, increased intratumoral lymphocyte infiltration, 
and enhanced antigen-specific antitumor responses, particularly 
in combination with DC-based immunotherapy (56). OV deliv-
ery of cytotoxic compounds or prodrug-activating enzymes can 
induce localized tumor damage without systemic side effects (56). 
AD5-CD/TKrep, an adenovirus expressing a cytosine deaminase/
thymidine kinase (CD/TK) fusion protein that locally activates 
5-fluorocytosine and ganciclovir pro-drugs, has been evaluated in 
two phase I clinical trials in patients with prostate cancer (9, 57).
FUTURe DiReCTiOn
The future of OVT will focus on understanding and optimizing 
the complex interactions between OVs, tumor cells, and the host 
immune system. Elucidating relationships between factors such 
as patient immune status, malignancy type, tumor mutation pro-
files, and OV vector species, and patient responses to virotherapy 
will aid in the development of more efficacious, personalized 
treatments. Exploration of methods to improve OV access and 
delivery to tumor sites in terms of optimizing cell carrier-based 
delivery systems that maximize the therapeutic payload to the 
TME at the same time modulating host immune system are also 
promising areas of research. Overall, the most effective anticancer 
treatments will likely utilize a combination of therapies with dif-
ferent, synergistic mechanisms of tumor destruction.
COnClUSiOn
Oncolytic virotherapy is a novel approach to cancer treatment, 
uniquely combining direct cytotoxicity with antitumor immu-
notherapy. Clinical trials have established the safety and clinical 
efficacy of OVs, culminating in the recent FDA approval of the 
OV, T-VEC for treatment of malignant melanoma. An improved 
understanding of the relationships between OVs, tumors, and the 
host immune system will be necessary in the development of the 
next generation of OVs. Future OVs with improved tumor selec-
tivity and cytotoxicity delivered in combination with immune-
modulating therapies will significantly enhance the contribution 
of OVT to the field of oncology.
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